O	0	13	Effectiveness
O	14	16	of
B-intervention	17	19	OK
I-intervention	19	20	-
I-intervention	20	23	432
I-intervention	24	25	(
I-intervention	25	32	Sapylin
I-intervention	32	33	)
O	34	36	to
O	37	43	reduce
B-condition	44	50	seroma
I-condition	51	60	formation
O	61	66	after
O	67	75	axillary
O	76	91	lymphadenectomy
O	92	95	for
O	96	102	breast
O	103	109	cancer
O	109	110	.

O	111	114	The
O	115	125	occurrence
O	126	128	of
O	129	135	seroma
O	136	145	formation
O	146	151	after
O	152	160	axillary
O	161	176	lymphadenectomy
O	177	180	for
O	181	187	breast
O	188	194	cancer
O	195	201	cannot
O	202	204	be
O	205	212	ignored
O	212	213	.

O	214	221	Various
O	222	232	approaches
O	233	237	have
O	238	242	been
O	243	247	used
O	248	250	in
O	251	253	an
O	254	260	effort
O	261	263	to
O	264	270	reduce
O	271	273	it
O	273	274	,
O	275	278	but
O	279	284	these
O	285	292	results
O	293	296	are
O	297	302	still
O	303	316	controversial
O	316	317	.

O	318	320	We
O	321	326	aimed
O	327	329	to
O	330	338	describe
O	339	340	a
O	341	344	new
O	345	351	method
O	352	354	of
O	355	366	application
O	367	369	of
O	370	372	OK
O	372	373	-
O	373	376	432
O	377	378	(
O	378	385	Sapylin
O	385	386	,
O	387	391	heat
O	391	392	-
O	392	399	treated
O	400	402	Su
O	403	409	strain
O	410	412	of
O	413	426	Streptococcus
O	426	427	)
O	428	430	to
O	431	437	reduce
O	438	444	seroma
O	445	454	formation
O	455	460	after
O	461	469	axillary
O	470	485	lymphadenectomy
O	486	489	for
O	490	496	breast
O	497	503	cancer
O	504	507	and
O	508	510	to
O	511	517	verify
O	518	521	the
O	522	528	safety
O	529	532	and
O	533	541	efficacy
O	542	544	of
O	545	547	it
O	548	550	as
O	551	552	a
O	553	563	beneficial
O	564	574	supplement
O	575	578	for
O	579	591	conventional
O	592	599	surgery
O	599	600	.

O	601	602	A
O	603	614	prospective
O	614	615	,
O	616	626	randomized
O	627	635	analysis
O	636	638	of
O	639	650	consecutive
O	651	665	quadrantectomy
O	666	668	or
O	669	679	mastectomy
O	680	684	plus
O	685	693	axillary
O	694	709	lymphadenectomy
O	710	715	using
O	716	718	or
O	719	722	not
O	723	728	using
O	729	731	OK
O	731	732	-
O	732	735	432
O	736	739	was
O	740	748	designed
O	748	749	.

O	750	754	From
O	755	759	July
O	760	764	2010
O	765	767	to
O	768	776	November
O	777	781	2011
O	781	782	,
O	783	784	a
O	785	790	total
O	791	793	of
B-total-participants	794	797	111
O	798	806	patients
O	807	811	were
O	812	820	enrolled
O	821	823	in
O	824	828	this
O	829	840	prospective
O	840	841	,
O	842	852	randomized
O	853	858	study
O	859	862	and
O	863	872	completed
O	873	876	the
O	877	883	follow
O	883	884	-
O	884	886	up
O	886	887	.

O	888	890	OK
O	890	891	-
O	891	894	432
O	895	902	applied
O	903	905	to
O	906	909	the
O	910	918	axillary
O	919	924	fossa
O	925	929	plus
O	930	939	placement
O	940	942	of
O	943	949	closed
O	950	957	suction
O	958	966	drainage
O	967	970	was
O	971	975	used
O	976	978	in
B-intervention-participants	979	981	54
O	982	990	patients
O	991	992	(
O	992	995	the
O	996	1008	experimental
O	1009	1014	group
O	1014	1015	)
O	1015	1016	;
O	1017	1026	placement
O	1027	1029	of
O	1030	1036	closed
O	1037	1044	suction
O	1045	1053	drainage
O	1054	1057	was
O	1058	1062	used
O	1063	1065	in
B-control-participants	1066	1068	57
O	1069	1077	patients
O	1078	1079	(
O	1079	1082	the
B-control	1083	1090	control
I-control	1091	1096	group
O	1096	1097	)
O	1097	1098	.

O	1099	1104	There
O	1105	1109	were
O	1110	1112	no
O	1113	1124	statistical
O	1125	1137	significance
O	1138	1145	between
O	1146	1149	the
O	1150	1153	two
O	1154	1160	groups
O	1161	1163	in
O	1164	1169	terms
O	1170	1172	of
O	1173	1176	age
O	1176	1177	,
O	1178	1182	body
O	1183	1187	mass
O	1188	1193	index
O	1193	1194	,
O	1195	1204	treatment
O	1205	1213	received
O	1213	1214	,
O	1215	1220	tumor
O	1221	1225	size
O	1225	1226	,
O	1227	1233	number
O	1234	1236	of
O	1237	1244	removed
O	1245	1250	lymph
O	1251	1256	nodes
O	1256	1257	,
O	1258	1261	and
O	1262	1267	lymph
O	1268	1272	node
O	1273	1279	status
O	1279	1280	.

B-outcome	1281	1294	Postoperative
I-outcome	1295	1303	drainage
I-outcome	1304	1313	magnitude
I-outcome	1314	1317	and
I-outcome	1318	1326	duration
O	1327	1331	were
O	1332	1345	significantly
O	1346	1353	reduced
O	1354	1356	in
O	1357	1360	the
O	1361	1373	experimental
O	1374	1379	group
O	1380	1381	(
O	1381	1382	P
O	1383	1384	=
O	1385	1386	0
O	1386	1387	.
O	1387	1390	008
O	1391	1394	and
O	1395	1396	0
O	1396	1397	.
O	1397	1400	003
O	1400	1401	,
O	1402	1414	respectively
O	1414	1415	)
O	1415	1416	.

O	1417	1420	One
O	1421	1425	week
O	1426	1431	after
O	1432	1440	hospital
O	1441	1450	discharge
O	1450	1451	,
O	1452	1457	fewer
O	1458	1466	patients
O	1467	1476	developed
O	1477	1478	a
B-outcome	1479	1487	palpable
I-outcome	1488	1494	seroma
O	1495	1497	in
O	1498	1501	the
O	1502	1514	experimental
O	1515	1520	group
O	1520	1521	:
B-iv-bin-abs	1522	1524	10
O	1525	1527	in
O	1528	1531	the
O	1532	1544	experimental
O	1545	1550	group
O	1551	1557	versus
B-cv-bin-abs	1558	1560	28
O	1561	1563	in
O	1564	1567	the
O	1568	1575	control
O	1576	1581	group
O	1582	1583	(
O	1583	1584	P
O	1585	1586	=
O	1587	1588	0
O	1588	1589	.
O	1589	1592	001
O	1592	1593	)
O	1593	1594	.

O	1595	1600	Fewer
B-outcome	1601	1608	seromas
I-outcome	1609	1615	needed
I-outcome	1616	1626	aspiration
O	1627	1628	(
O	1628	1632	mean
B-iv-cont-mean	1633	1634	1
O	1635	1636	[
O	1636	1641	range
O	1642	1643	0
O	1643	1644	-
O	1644	1645	3
O	1645	1646	]
O	1647	1649	in
O	1650	1653	the
O	1654	1666	experimental
O	1667	1672	group
O	1673	1675	vs
O	1675	1676	.
O	1677	1681	mean
B-cv-cont-mean	1682	1683	4
O	1684	1685	[
O	1685	1690	range
O	1691	1692	1
O	1692	1693	-
O	1693	1694	5
O	1694	1695	]
O	1696	1698	in
O	1699	1702	the
O	1703	1710	control
O	1711	1716	group
O	1716	1717	;
O	1718	1719	P
O	1720	1721	<
O	1722	1723	0
O	1723	1724	.
O	1724	1727	001
O	1727	1728	)
O	1728	1729	.

O	1730	1735	There
O	1736	1740	were
O	1741	1743	no
O	1744	1755	significant
O	1756	1767	differences
O	1768	1770	in
O	1771	1776	terms
O	1777	1779	of
O	1780	1783	the
B-outcome	1784	1793	incidence
I-outcome	1794	1796	of
I-outcome	1797	1810	complications
I-outcome	1811	1821	associated
I-outcome	1822	1826	with
I-outcome	1827	1835	axillary
I-outcome	1836	1851	lymphadenectomy
O	1852	1853	(
O	1853	1854	P
O	1855	1856	=
O	1857	1858	0
O	1858	1859	.
O	1859	1862	941
O	1862	1863	)
O	1863	1864	.

O	1865	1867	OK
O	1867	1868	-
O	1868	1871	432
O	1872	1874	is
O	1875	1876	a
O	1877	1885	feasible
O	1886	1889	and
O	1890	1894	safe
O	1895	1901	option
O	1902	1905	for
O	1906	1914	axillary
O	1915	1930	lymphadenectomy
O	1931	1934	for
O	1935	1941	breast
O	1942	1948	cancer
O	1948	1949	.

O	1950	1953	The
O	1954	1957	use
O	1958	1960	of
O	1961	1963	it
O	1964	1968	does
O	1969	1972	not
O	1973	1979	always
O	1980	1987	prevent
O	1988	1994	seroma
O	1995	2004	formation
O	2004	2005	,
O	2006	2009	but
O	2010	2012	it
O	2013	2016	can
O	2017	2023	reduce
O	2024	2032	drainage
O	2033	2042	magnitude
O	2043	2046	and
O	2047	2055	duration
O	2055	2056	,
O	2057	2059	as
O	2060	2064	well
O	2065	2067	as
O	2068	2076	decrease
O	2077	2080	the
O	2081	2090	incidence
O	2091	2093	of
O	2094	2100	seroma
O	2101	2106	after
O	2107	2110	the
O	2111	2118	removal
O	2119	2121	of
O	2122	2130	drainage
O	2130	2131	.

O	2132	2134	It
O	2135	2138	may
O	2139	2141	be
O	2142	2154	increasingly
O	2155	2164	conducted
O	2165	2167	in
O	2168	2171	day
O	2172	2179	surgery
O	2180	2187	clinics
O	2187	2188	.
